Despite the availability of generic competitors, Bristol Myers Squibb posted Revlimid sales of $2.5 billion for the second quarter of 2022, beating out analyst expectations. BMS said in its earnings report it expects total Revlimid sales of $9.0 to $9.5 billion for the full year. Teva Pharmaceuticals launched Lenalidomide, the first Revlimid generic available in the U.S., in May. Other generic competitors are available internationally, and more copies are set to arrive in the U.S. later this year. For the treatment of multiple myeloma, Lenalidomide holds preferred generic status for 19% of all insured lives under the pharmacy benefit. Revlimid, meanwhile, is a preferred multiple myeloma drug for 52% of insured lives.
SOURCE: MMIT Analytics, as of 8/1/22